← Leaderboards
Timothy Mayall
Paxvax, Inc.
$894,281
Attributed
$2,532,843
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2010–14$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,532,843 · 3
By mechanism
R44$1,971,235 · 1
R43$561,608 · 2
Top collaborators
- Marc Joseph Gurwith4 shared
- Jeffery Alexander3 shared
Most similar at Paxvax, Inc.
Same institution · by research overlap
- Marc Joseph Gurwith$21,974,740
- Jeffery Alexander$1,764,192
Others in their field
Top investigators on “Mucosal Immune Responses”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$451,633,628
- Lawrence Corey · Fred Hutchinson Cancer Center$254,998,765
- Barton F Haynes · Duke University$134,411,312
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,449,900
- Ted Ross · University Of Georgia$63,112,979
- Dan H. Barouch · Fred Hutchinson Cancer Center$55,141,176
Research focus
Mucosal Immune ResponsesNovel StrategiesInjection Of Therapeutic AgentMolecular ConformationMucous MembraneNeutralizing AntibodyImmune ResponseImmunogenicityMeasles VaccineMilitary PersonnelEnv Gene ProductsHiv VaccineAntibody FormationHiv Envelope Protein Gp120AntibodiesEngineeringAcquired Immunodeficiency SyndromeImmunizationBaseLifeAdenovirusesDosage FormsAnimalsOral
Grant awards (4)
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$971,235
R44 · FY2014 · AI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$1,000,000
R44 · FY2012 · AI
Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2$261,608
R43 · FY2012 · AI
Ad4 vectored HIV-Env vaccines with improved immunogenicity$300,000
R43 · FY2010 · AI